Sudden unexpected death in epilepsy genetics: Molecular diagnostics and prevention

Epilepsia

Volumn 57, Issue , 2016, Pages 17-25

  Goldman, Alica M ^a   Behr, Elijah R ^b   Semsarian, Christopher ^c   Bagnall, Richard D ^c   Sisodiya, Sanjay ^d   Cooper, Paul N ^e,f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Greater Manchester Neurosciences Centre   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Molecular autopsy; Prevention; Sudden cardiac death; Sudden infant death syndrome; Sudden unexpected death in epilepsy (SUDEP), genetics

Indexed keywords

AROUSAL; AUSTRALIAN; AUTOPSY; BREATHING; CONFERENCE PAPER; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MOLECULAR DIAGNOSIS; MOLECULAR GENETICS; POPULATION GENETICS; PRIORITY JOURNAL; SUDDEN CARDIAC DEATH; SUDDEN DEATH; SUDDEN INFANT DEATH SYNDROME; TRANSLATIONAL RESEARCH; DEATH, SUDDEN, CARDIAC; EPILEPSY; GENETIC PREDISPOSITION; GENETICS; HEART ARRHYTHMIA; INFANT; PREVENTION AND CONTROL;

HCN2 PROTEIN, HUMAN; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL; KCNA1 PROTEIN, HUMAN; KCNQ1 PROTEIN, HUMAN; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KV1.1; SCN1A PROTEIN, HUMAN; SCN5A PROTEIN, HUMAN; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.5;

ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN; DEATH, SUDDEN, CARDIAC; EPILEPSY; ERG1 POTASSIUM CHANNEL; ETHER-A-GO-GO POTASSIUM CHANNELS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNELS; INFANT; KCNQ1 POTASSIUM CHANNEL; KV1.1 POTASSIUM CHANNEL; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; POTASSIUM CHANNELS; SUDDEN INFANT DEATH;

EID: 84954148489     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13232     Document Type: Conference Paper

References (117)

1. Nashef L, Garner S, Sander JW, et al., Circumstances of death in sudden death in epilepsy: interviews of bereaved relatives. J Neurol Neurosurg Psychiatry 1998; 64: 349-352.
2. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al., Task force on sudden cardiac death of the European Society of cardiology. Eur Heart J 2001; 22: 1374-1450.
3. Papadakis M, Sharma S, Cox S, et al., The magnitude of sudden cardiac death in the young: a death certificate-based review in England and Wales. Europace 2009; 11: 1353-1358.
4. Behr ER, Casey A, Sheppard M, et al., Sudden arrhythmic death syndrome: a national survey of sudden unexplained cardiac death. Heart 2007; 93: 601-605.
5. Raju H, Behr ER,. Unexplained sudden death, focussing on genetics and family phenotyping. Curr Opin Cardiol 2013; 28: 19-25.
6. Bastiaenen R, Behr ER,. Sudden death and ion channel disease: pathophysiology and implications for management. Heart 2011; 97: 1365-1372.
7. Bezzina CR, Barc J, Mizusawa Y, et al., Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013; 45: 1044-1049.
8. Jamshidi Y, Nolte IM, Dalageorgou C, et al., Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol 2012; 60: 841-850.
9. Arking DE, Junttila MJ, Goyette P, et al., Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals. PLoS Genet 2011; 7: e1002158.
10. Bezzina CR, Pazoki R, Bardai A, et al., Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nat Genet 2010; 42: 688-691.
11. Raju H, Alberg C, Sagoo GS, et al., Inherited cardiomyopathies. BMJ 2011; 343: d6966.
12. Wilde AA, Behr ER,. Genetic testing for inherited cardiac disease. Nat Rev Cardiol 2013; 10: 571-583.
13. Semsarian C, Hamilton RM,. Key role of the molecular autopsy in sudden unexpected death. Heart Rhythm 2012; 9: 145-150.
14. Tester DJ, Medeiros-Domingo A, Will ML, et al., Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc 2012; 87: 524-539.
15. Behr E, Wood DA, Wright M, et al., Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome. Lancet 2003; 362: 1457-1459.
16. Behr ER, Dalageorgou C, Christiansen M, et al., Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. Eur Heart J 2008; 29: 1670-1680.
17. Westenskow P, Splawski I, Timothy KW, et al., Compound mutations: a common cause of severe long-QT syndrome. Circulation 2004; 109: 1834-1841.
18. Jouven X, Desnos M, Guerot C, et al., Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999; 99: 1978-1983.
19. Splawski I, Timothy KW, Tateyama M, et al., Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002; 297: 1333-1336.
20. Burke A, Creighton W, Mont E, et al., Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation 2005; 112: 798-802.
21. Plant LD, Bowers PN, Liu Q, et al., A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J Clin Invest 2006; 116: 430-435.
22. Dekker LR, Bezzina CR, Henriques JP, et al., Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation 2006; 114: 1140-1145.
23. Marsman RF, Bezzina CR, Freiberg F, et al., Coxsackie and adenovirus receptor is a modifier of cardiac conduction and arrhythmia vulnerability in the setting of myocardial ischemia. J Am Coll Cardiol 2014; 63: 549-559.
24. Arking DE, Pulit SL, Crotti L, et al., Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nat Genet 2014; 46: 826-836.
25. Crotti L, Monti MC, Insolia R, et al., NOS1AP is a genetic modifier of the long-QT syndrome. Circulation 2009; 120: 1657-1663.
26. Kao WH, Arking DE, Post W, et al., Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation 2009; 119: 940-951.
27. Behr ER, Roden D,. Drug-induced arrhythmia: pharmacogenomic prescribing? Eur Heart J 2013; 34: 89-95.
28. Kaab S, Crawford DC, Sinner MF, et al., A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 2012; 5: 91-99.
29. Roden DM,. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21: 1029-1034.
30. Hartmann HA, Colom LV, Sutherland ML, et al., Selective localization of cardiac SCN5A sodium channels in limbic regions of rat brain. Nat Neurosci 1999; 2: 593-595.
31. Aurlien D, Leren TP, Tauboll E, et al., New SCN5A mutation in a SUDEP victim with idiopathic epilepsy. Seizure 2009; 18: 158-160.
32. Heron SE, Hernandez M, Edwards C, et al., Neonatal seizures and long QT syndrome: a cardiocerebral channelopathy? Epilepsia 2010; 51: 293-296.
33. Goldman AM, Glasscock E, Yoo J, et al., Arrhythmia in heart and brain: KCNQ1 mutations link epilepsy and sudden unexplained death. Sci Transl Med 2009; 1: 2ra6.
34. Bird J, Dembny KAT, Sandeman D, et al., Sudden unexplained death in epilepsy: an intracranially monitored case. Epilepsia 1997; 38 (Suppl. 11): S52-S56.
35. Anderson JH, Bos JM, Cascino GD, et al., Prevalence and spectrum of electroencephalogram-identified epileptiform activity among patients with long QT syndrome. Heart Rhythm 2014; 11: 53-57.
36. Keller DI, Grenier J, Christe G, et al., Characterization of novel KCNH2 mutations in type 2 long QT syndrome manifesting as seizures. Can J Cardiol 2009; 25: 455-462.
37. Partemi S, Cestele S, Pezzella M, et al., Loss-of-function KCNH2 mutation in a family with long QT syndrome, epilepsy, and sudden death. Epilepsia 2013; 54: e112-e116.
38. Tu E, Bagnall RD, Duflou J, et al., Post-mortem review and genetic analysis of sudden unexpected death in epilepsy (SUDEP) cases. Brain Pathol 2011; 21: 201-208.
39. Postma AV, Denjoy I, Kamblock J, et al., Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 2005; 42: 863-870.
40. Liu N, Priori SG,. Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin. Cardiovasc Res 2008; 77: 293-301.
41. 2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 2008; 118: 2230-2245.
42. Johnson JN, Tester DJ, Bass NE, et al., Cardiac channel molecular autopsy for sudden unexpected death in epilepsy. J Child Neurol 2010; 25: 916-921.
43. Noam Y, Bernard C, Baram TZ,. Towards an integrated view of HCN channel role in epilepsy. Curr Opin Neurobiol 2011; 21: 873-879.
44. Benarroch EE,. HCN channels: function and clinical implications. Neurology 2013; 80: 304-310.
45. Monteggia LM, Eisch AJ, Tang MD, et al., Cloning and localization of the hyperpolarization-activated cyclic nucleotide-gated channel family in rat brain. Brain Res Mol Brain Res 2000; 81: 129-139.
46. Meuth SG, Kanyshkova T, Meuth P, et al., Membrane resting potential of thalamocortical relay neurons is shaped by the interaction among TASK3 and HCN2 channels. J Neurophysiol 2006; 96: 1517-1529.
47. Marionneau C, Couette B, Liu J, et al., Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart. J Physiol 2005; 562 (Pt 1): 223-234.
48. Stieber J, Wieland K, Stockl G, et al., Bradycardic and proarrhythmic properties of sinus node inhibitors. Mol Pharmacol 2006; 69: 1328-1337.
49. Ludwig A, Budde T, Stieber J, et al., Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2. EMBO J 2003; 22: 216-224.
50. Tu E, Waterhouse L, Duflou J, et al., Genetic analysis of hyperpolarization-activated cyclic nucleotide-gated cation channels in sudden unexpected death in epilepsy cases. Brain Pathol 2011; 21: 692-698.
51. Glasscock E, Yoo JW, Chen TT, et al., Kv1.1 potassium channel deficiency reveals brain-driven cardiac dysfunction as a candidate mechanism for sudden unexplained death in epilepsy. J Neurosci 2010; 30: 5167-5175.
52. Klassen TL, Bomben VC, Patel A, et al., High-resolution molecular genomic autopsy reveals complex sudden unexpected death in epilepsy risk profile. Epilepsia 2014; 55: e6-e12.
53. Hindocha N, Nashef L, Elmslie F, et al., Two cases of sudden unexpected death in epilepsy in a GEFS+ family with an SCN1A mutation. Epilepsia 2008; 49: 360-365.
54. Genton P, Velizarova R, Dravet C,. Dravet syndrome: the long-term outcome. Epilepsia 2011; 52 (Suppl. 2): S44-S49.
55. Skluzacek JV, Watts KP, Parsy O, et al., Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia 2011; 52 (Suppl. 2): S95-S101.
56. Sakauchi M, Oguni H, Kato I, et al., Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. Epilepsia 2011; 52: 1144-1149.
57. Delogu AB, Spinelli A, Battaglia D, et al., Electrical and autonomic cardiac function in patients with Dravet syndrome. Epilepsia 2011; 52 (Suppl. 2): S55-S58.
58. Ergul Y, Ekici B, Tatli B, et al., QT and P wave dispersion and heart rate variability in patients with Dravet syndrome. Acta Neurol Belg 2013; 113: 161-166.
59. Cheah CS, Yu FH, Westenbroek RE, et al., Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A 2012; 109: 14646-14651.
60. Kalume F, Westenbroek RE, Cheah CS, et al., Sudden unexpected death in a mouse model of Dravet syndrome. J Clin Invest 2013; 123: 1798-1808.
61. Ogiwara I, Iwasato T, Miyamoto H, et al., Nav1.1 haploinsufficiency in excitatory neurons ameliorates seizure-associated sudden death in a mouse model of Dravet syndrome. Hum Mol Genet 2013; 22: 4784-4804.
62. Auerbach DS, Jones J, Clawson BC, et al., Altered cardiac electrophysiology and SUDEP in a model of Dravet syndrome. PLoS ONE 2013; 8: e77843.
63. Brackenbury WJ, Yuan Y, O'Malley HA, et al., Abnormal neuronal patterning occurs during early postnatal brain development of Scn1b-null mice and precedes hyperexcitability. Proc Natl Acad Sci U S A 2013; 110: 1089-1094.
64. +-channel beta1 subunit gene SCN1B. Nat Genet 1998; 19: 366-370.
65. Scheffer IE, Harkin LA, Grinton BE, et al., Temporal lobe epilepsy and GEFS+ phenotypes associated with SCN1B mutations. Brain 2007; 130: 100-109.
66. Ogiwara I, Nakayama T, Yamagata T, et al., A homozygous mutation of voltage-gated sodium channel beta(I) gene SCN1B in a patient with Dravet syndrome. Epilepsia 2012; 53: e200-e203.
67. Chen C, Westenbroek RE, Xu X, et al., Mice lacking sodium channel beta1 subunits display defects in neuronal excitability, sodium channel expression, and nodal architecture. J Neurosci 2004; 24: 4030-4042.
68. Lopez-Santiago LF, Meadows LS, Ernst SJ, et al., Sodium channel Scn1b null mice exhibit prolonged QT and RR intervals. J Mol Cell Cardiol 2007; 43: 636-647.
69. Kash SF, Johnson RS, Tecott LH, et al., Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci U S A 1997; 94: 14060-14065.
70. Veeramah KR, O'Brien JE, Meisler MH, et al., De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet 2012; 90: 502-510.
71. Hawkins NA, Martin MS, Frankel WN,. Neuronal voltage-gated ion channels are genetic modifiers of generalized epilepsy with febrile seizures plus. Neurobiol Dis 2011; 41: 655-660.
72. O'Brien JE, Meisler MH,. Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability. Front Genet 2013; 4: 213.
73. Weckhuysen S, Ivanovic V, Hendrickx R, et al., Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology 2013; 81: 1697-1703.
74. Tecott LH, Sun LM, Akana SF, et al., Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542-546.
75. Tupal S, Faingold CL,. Evidence supporting a role of serotonin in modulation of sudden death induced by seizures in DBA/2 mice. Epilepsia 2006; 47: 21-26.
76. Richerson GB, Buchanan GF,. The serotonin axis: shared mechanisms in seizures, depression, and SUDEP. Epilepsia 2011; 52 (Suppl. 1): S28-S38.
77. Sowers LP, Massey CA, Gehlbach BK, et al., Sudden unexpected death in epilepsy: fatal post-ictal respiratory and arousal mechanisms. Respir Physiol Neurobiol 2013; 189: 315-323.
78. Bateman LM, Li CS, Lin TC, et al., Serotonin reuptake inhibitors are associated with reduced severity of ictal hypoxemia in medically refractory partial epilepsy. Epilepsia 2010; 51: 2211-2214.
79. Massey CA, Sowers LP, Dlouhy BJ, et al., Mechanisms of sudden unexpected death in epilepsy: the pathway to prevention. Nat Rev Neurol 2014; 10: 271-282.
80. Hodges MR, Wehner M, Aungst J, et al., Transgenic mice lacking serotonin neurons have severe apnea and high mortality during development. J Neurosci 2009; 29: 10341-10349.
81. Uteshev VV, Tupal S, Mhaskar Y, et al., Abnormal serotonin receptor expression in DBA/2 mice associated with susceptibility to sudden death due to respiratory arrest. Epilepsy Res 2010; 88: 183-188.
82. Faingold CL, Randall M,. Effects of age, sex, and sertraline administration on seizure-induced respiratory arrest in the DBA/1 mouse model of sudden unexpected death in epilepsy (SUDEP). Epilepsy Behav 2013; 28: 78-82.
83. Faingold CL, Tupal S, Randall M,. Prevention of seizure-induced sudden death in a chronic SUDEP model by semichronic administration of a selective serotonin reuptake inhibitor. Epilepsy Behav 2011; 22: 186-190.
84. Mullally J, Goldenberg I, Moss AJ, et al., Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations. Heart Rhythm 2013; 10: 378-382.
85. Yoshikane Y, Yoshinaga M, Hamamoto K, et al., A case of long QT syndrome with triple gene abnormalities: digenic mutations in KCNH2 and SCN5A and gene variant in KCNE1. Heart Rhythm 2013; 10: 600-603.
86. Veeramah KR, Johnstone L, Karafet TM, et al., Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia 2013; 54: 1270-1281.
87. Epi4K Consortium; Epilepsy Phenome/Genome Project. De novo mutations in epileptic encephalopathies. Nature 2013; 501: 217-221.
88. Carvill GL, Heavin SB, Yendle SC, et al., Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 2013; 45: 825-830.
89. Glasscock E, Qian J, Yoo JW, et al., Masking epilepsy by combining two epilepsy genes. Nat Neurosci 2007; 10: 1554-1558.
90. Holth JK, Bomben VC, Reed JG, et al., Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci 2013; 33: 1651-1659.
91. Swan H, Viitasalo M, Piippo K, et al., Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects. J Am Coll Cardiol 1999; 34: 823-829.
92. Fodstad H, Swan H, Laitinen P, et al., Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland. Ann Med 2004; 36 (Suppl. 1): 53-63.
93. Larsen LA, Andersen PS, Kanters J, et al., Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MiRP1 ion channel: implications for acquired and congenital long Q-T syndrome. Clin Chem 2001; 47: 1390-1395.
94. Tester DJ, Ackerman MJ,. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol 2007; 49: 240-246.
95. Kapplinger JD, Tester DJ, Salisbury BA, et al., Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm 2009; 6: 1297-1303.
96. Albert CM, Nam EG, Rimm EB, et al., Cardiac sodium channel gene variants and sudden cardiac death in women. Circulation 2008; 117: 16-23.
97. Krahn AD, Healey JS, Chauhan V, et al., Systematic assessment of patients with unexplained cardiac arrest: cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). Circulation 2009; 120: 278-285.
98. Priori SG, Napolitano C, Schwartz PJ, et al., The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 2000; 102: 945-947.
99. Ackerman MJ, Priori SG, Willems S, et al., HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8: 1308-1339.
100. Iwasa H, Itoh T, Nagai R, et al., Twenty single nucleotide polymorphisms (SNPs) and their allelic frequencies in four genes that are responsible for familial long QT syndrome in the Japanese population. J Hum Genet 2000; 45: 182-183.
101. Bagnall RD, Das KJ, Duflou J, et al., Exome analysis based molecular autopsy in cases of sudden unexplained death in the young. Heart Rhythm 2014; 11: 655-662.
102. International League Against Epilepsy Consortium on Complex Epilepsies. Electronic address e-auea. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol 2014; 13: 893-903.
103. Jeffs TC, Donner EJ,. Our epilepsy story: SUDEP aware. Epilepsia 2015; 56: 9-11.
104. Klassen TL, von Ruden EL, Drabek J, et al., Comparative analytical utility of DNA derived from alternative human specimens for molecular autopsy and diagnostics. J Mol Diagn 2012; 14: 451-457.
105. Novy J, Belluzzo M, Caboclo LO, et al., The lifelong course of chronic epilepsy: the Chalfont experience. Brain 2013; 136: 3187-3199.
106. Nashef L, Hindocha N, Makoff A,. Risk factors in sudden death in epilepsy (SUDEP): the quest for mechanisms. Epilepsia 2007; 48: 859-871.
107. Tester DJ, Ackerman MJ,. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation 2011; 123: 1021-1037.
108. Zaidi A, Clough P, Cooper P, et al., Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol 2000; 36: 181-184.
109. Viskin S, Rosovski U, Sands AJ, et al., Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005; 2: 569-574.
110. Davis S, Westby M, Petkar S, et al., Tilt testing is more cost-effective than implantable loop recorder monitoring as a means of directing pacing therapy in people with recurrent episodes of suspected vasovagal syncope that affect their quality of life or present a high risk of injury. Heart 2013; 99: 805-810.
111. Chadwick D, Jelen P, Almond S,. Life and death diagnosis. Pract Neurol 2010; 10: 155-159.
112. Russell AE,. Cessation of the pulse during the onset of epileptic fits,: with remarks on the mechanism of fits. Lancet 1906; 168: 152-154.
113. Rugg-Gunn FJ, Simister RJ, Squirrell M, et al., Cardiac arrhythmias in focal epilepsy: a prospective long-term study. Lancet 2004; 364: 2212-2219.
114. Nashef L, Walker F, Allen P, et al., Apnoea and bradycardia during epileptic seizures: relation to sudden death in epilepsy. J Neurol Neurosurg Psychiatry 1996; 60: 297-300.
115. Persson H, Ericson M, Tomson T,. Heart rate variability in patients with untreated epilepsy. Seizure 2007; 16: 504-508.
116. Ansakorpi H, Korpelainen JT, Suominen K, et al., Interictal cardiovascular autonomic responses in patients with temporal lobe epilepsy. Epilepsia 2000; 41: 42-47.
117. Lossius MI, Erikssen JE, Mowinckel P, et al., Changes in autonomic cardiac control in patients with epilepsy after discontinuation of antiepileptic drugs: a randomized controlled withdrawal study. Eur J Neurol 2007; 14: 1022-1028.